Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name CSF1R over exp
Gene Variant Detail

CSF1R over exp (no effect)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
CSF1R over exp tenosynovial giant cell tumor sensitive Pexidartinib Phase I Actionable In a Phase I trial, PLX3397 reduced tenosynovial giant cell tumor volume in patients with overexpression of Csf1r (PMID: 26222558). 26222558
CSF1R over exp acute myeloid leukemia sensitive Narazaciclib Preclinical - Pdx & cell culture Actionable In a preclinical study, Narazaciclib (ON123300) inhibited proliferation of acute myeloid leukemia cell lines harboring CSF1R overexpression in culture, and decreased the leukemic burden in the spleen and bone in a patient-derived xenograft (PDX) model (PMID: 38641704). 38641704
CSF1R over exp acute myeloid leukemia sensitive Cytarabine + Narazaciclib Preclinical - Pdx Actionable In a preclinical study, treatment with the combination of Narazaciclib (ON123300) and Cytosar-U (cytarabine) reduced tumor burden in a patient-derived xenograft (PDX) model of acute myeloid leukemia with CSF1R overexpression (PMID: 38641704). 38641704